Beconase Aq

Cellulitis, Asthma, Nasal Polyps + 10 more

Treatment

20 Active Studies for Beconase Aq

What is Beconase Aq

Beclomethasone dipropionate

The Generic name of this drug

Treatment Summary

Beclomethasone dipropionate is an anti-inflammatory medication used to treat conditions like asthma, allergic rhinitis, and dermatoses. It comes in the form of an inhaler, dry powder inhaler, or an aqueous nasal spray. Beclomethasone dipropionate works by targeting the glucocorticoid receptor, reducing inflammation and providing relief from symptoms. Compared to earlier corticosteroids, beclomethasone dipropionate has a longer-lasting effect and is less irritating to the nasal mucosa.

Beconase AQ

is the brand name

image of different drug pills on a surface

Beconase Aq Overview & Background

Brand Name

Generic Name

First FDA Approval

How many FDA approvals?

Beconase AQ

Beclomethasone dipropionate

1989

29

Effectiveness

How Beconase Aq Affects Patients

Beclomethasone dipropionate is a drug used to treat asthma, allergies, and skin conditions. When taken, it reduces inflammation and improves lung function. It is mainly inhaled, but long-term use can lead to decreased hormone production and bone issues. It may also increase the risk of infections due to the suppression of the immune system. Inhaling beclomethasone dipropionate can cause a fungal infection in the mouth and throat.

How Beconase Aq works in the body

Beclomethasone dipropionate is a corticosteroid that works to reduce inflammation. After being activated, it binds to glucocorticoid receptors in the nucleus which then bind to genes that reduce inflammation. Corticosteroids also work by increasing the transcription of genes that code for anti-inflammatory proteins, and by inhibiting the expression of genes that code for pro-inflammatory proteins. This helps to reduce chronic inflammation by preventing the activity of inflammatory transcription factors and promoting histone deacetylation, which keeps DNA tightly coiled.

When to interrupt dosage

The proposed measure of Beconase Aq is dependent upon the diagnosed malady, such as Adrenal Cortex Hormones, Dermatosis and Nasal Polyps. The quantity of dosage relies upon the technique of application (e.g. Aerosol, metered; Suspension - Nasal or Powder - Respiratory (inhalation)) noted in the table beneath.

Condition

Dosage

Administration

Cellulitis

, 0.042 mg, 0.04 mg, 0.08 mg, 0.1 mg, 0.2 mg, 0.025 %, 0.25 mg/mL, 0.087 mg, 0.172 mg, 0.088 mg, 0.25 mg/pump actuation, 0.1 mg/pump actuation, 0.05 mg/pump actuation, 0.04 mg/pump actuation, 0.08 mg/pump actuation

, Spray, suspension, Nasal, Spray, suspension - Nasal, Aerosol, metered - Respiratory (inhalation), Respiratory (inhalation), Aerosol, metered, Suspension, Aerosol, metered; Suspension, Aerosol, metered; Suspension - Nasal, Suspension - Nasal, Powder, Powder - Respiratory (inhalation), Topical, Cream - Topical, Cream, Aerosol, metered - Nasal, Lotion - Topical, Lotion, Capsule - Respiratory (inhalation), Capsule, Spray - Nasal, Spray, Nasal; Respiratory (inhalation), Aerosol, metered - Nasal; Respiratory (inhalation)

Asthma

, 0.042 mg, 0.04 mg, 0.08 mg, 0.1 mg, 0.2 mg, 0.025 %, 0.25 mg/mL, 0.087 mg, 0.172 mg, 0.088 mg, 0.25 mg/pump actuation, 0.1 mg/pump actuation, 0.05 mg/pump actuation, 0.04 mg/pump actuation, 0.08 mg/pump actuation

, Spray, suspension, Nasal, Spray, suspension - Nasal, Aerosol, metered - Respiratory (inhalation), Respiratory (inhalation), Aerosol, metered, Suspension, Aerosol, metered; Suspension, Aerosol, metered; Suspension - Nasal, Suspension - Nasal, Powder, Powder - Respiratory (inhalation), Topical, Cream - Topical, Cream, Aerosol, metered - Nasal, Lotion - Topical, Lotion, Capsule - Respiratory (inhalation), Capsule, Spray - Nasal, Spray, Nasal; Respiratory (inhalation), Aerosol, metered - Nasal; Respiratory (inhalation)

Nasal Polyps

, 0.042 mg, 0.04 mg, 0.08 mg, 0.1 mg, 0.2 mg, 0.025 %, 0.25 mg/mL, 0.087 mg, 0.172 mg, 0.088 mg, 0.25 mg/pump actuation, 0.1 mg/pump actuation, 0.05 mg/pump actuation, 0.04 mg/pump actuation, 0.08 mg/pump actuation

, Spray, suspension, Nasal, Spray, suspension - Nasal, Aerosol, metered - Respiratory (inhalation), Respiratory (inhalation), Aerosol, metered, Suspension, Aerosol, metered; Suspension, Aerosol, metered; Suspension - Nasal, Suspension - Nasal, Powder, Powder - Respiratory (inhalation), Topical, Cream - Topical, Cream, Aerosol, metered - Nasal, Lotion - Topical, Lotion, Capsule - Respiratory (inhalation), Capsule, Spray - Nasal, Spray, Nasal; Respiratory (inhalation), Aerosol, metered - Nasal; Respiratory (inhalation)

Nasal Polyps

, 0.042 mg, 0.04 mg, 0.08 mg, 0.1 mg, 0.2 mg, 0.025 %, 0.25 mg/mL, 0.087 mg, 0.172 mg, 0.088 mg, 0.25 mg/pump actuation, 0.1 mg/pump actuation, 0.05 mg/pump actuation, 0.04 mg/pump actuation, 0.08 mg/pump actuation

, Spray, suspension, Nasal, Spray, suspension - Nasal, Aerosol, metered - Respiratory (inhalation), Respiratory (inhalation), Aerosol, metered, Suspension, Aerosol, metered; Suspension, Aerosol, metered; Suspension - Nasal, Suspension - Nasal, Powder, Powder - Respiratory (inhalation), Topical, Cream - Topical, Cream, Aerosol, metered - Nasal, Lotion - Topical, Lotion, Capsule - Respiratory (inhalation), Capsule, Spray - Nasal, Spray, Nasal; Respiratory (inhalation), Aerosol, metered - Nasal; Respiratory (inhalation)

Operation on nose

, 0.042 mg, 0.04 mg, 0.08 mg, 0.1 mg, 0.2 mg, 0.025 %, 0.25 mg/mL, 0.087 mg, 0.172 mg, 0.088 mg, 0.25 mg/pump actuation, 0.1 mg/pump actuation, 0.05 mg/pump actuation, 0.04 mg/pump actuation, 0.08 mg/pump actuation

, Spray, suspension, Nasal, Spray, suspension - Nasal, Aerosol, metered - Respiratory (inhalation), Respiratory (inhalation), Aerosol, metered, Suspension, Aerosol, metered; Suspension, Aerosol, metered; Suspension - Nasal, Suspension - Nasal, Powder, Powder - Respiratory (inhalation), Topical, Cream - Topical, Cream, Aerosol, metered - Nasal, Lotion - Topical, Lotion, Capsule - Respiratory (inhalation), Capsule, Spray - Nasal, Spray, Nasal; Respiratory (inhalation), Aerosol, metered - Nasal; Respiratory (inhalation)

Dermatosis

, 0.042 mg, 0.04 mg, 0.08 mg, 0.1 mg, 0.2 mg, 0.025 %, 0.25 mg/mL, 0.087 mg, 0.172 mg, 0.088 mg, 0.25 mg/pump actuation, 0.1 mg/pump actuation, 0.05 mg/pump actuation, 0.04 mg/pump actuation, 0.08 mg/pump actuation

, Spray, suspension, Nasal, Spray, suspension - Nasal, Aerosol, metered - Respiratory (inhalation), Respiratory (inhalation), Aerosol, metered, Suspension, Aerosol, metered; Suspension, Aerosol, metered; Suspension - Nasal, Suspension - Nasal, Powder, Powder - Respiratory (inhalation), Topical, Cream - Topical, Cream, Aerosol, metered - Nasal, Lotion - Topical, Lotion, Capsule - Respiratory (inhalation), Capsule, Spray - Nasal, Spray, Nasal; Respiratory (inhalation), Aerosol, metered - Nasal; Respiratory (inhalation)

Skin Diseases

, 0.042 mg, 0.04 mg, 0.08 mg, 0.1 mg, 0.2 mg, 0.025 %, 0.25 mg/mL, 0.087 mg, 0.172 mg, 0.088 mg, 0.25 mg/pump actuation, 0.1 mg/pump actuation, 0.05 mg/pump actuation, 0.04 mg/pump actuation, 0.08 mg/pump actuation

, Spray, suspension, Nasal, Spray, suspension - Nasal, Aerosol, metered - Respiratory (inhalation), Respiratory (inhalation), Aerosol, metered, Suspension, Aerosol, metered; Suspension, Aerosol, metered; Suspension - Nasal, Suspension - Nasal, Powder, Powder - Respiratory (inhalation), Topical, Cream - Topical, Cream, Aerosol, metered - Nasal, Lotion - Topical, Lotion, Capsule - Respiratory (inhalation), Capsule, Spray - Nasal, Spray, Nasal; Respiratory (inhalation), Aerosol, metered - Nasal; Respiratory (inhalation)

corticosteroid responsive

, 0.042 mg, 0.04 mg, 0.08 mg, 0.1 mg, 0.2 mg, 0.025 %, 0.25 mg/mL, 0.087 mg, 0.172 mg, 0.088 mg, 0.25 mg/pump actuation, 0.1 mg/pump actuation, 0.05 mg/pump actuation, 0.04 mg/pump actuation, 0.08 mg/pump actuation

, Spray, suspension, Nasal, Spray, suspension - Nasal, Aerosol, metered - Respiratory (inhalation), Respiratory (inhalation), Aerosol, metered, Suspension, Aerosol, metered; Suspension, Aerosol, metered; Suspension - Nasal, Suspension - Nasal, Powder, Powder - Respiratory (inhalation), Topical, Cream - Topical, Cream, Aerosol, metered - Nasal, Lotion - Topical, Lotion, Capsule - Respiratory (inhalation), Capsule, Spray - Nasal, Spray, Nasal; Respiratory (inhalation), Aerosol, metered - Nasal; Respiratory (inhalation)

Hay Fever

, 0.042 mg, 0.04 mg, 0.08 mg, 0.1 mg, 0.2 mg, 0.025 %, 0.25 mg/mL, 0.087 mg, 0.172 mg, 0.088 mg, 0.25 mg/pump actuation, 0.1 mg/pump actuation, 0.05 mg/pump actuation, 0.04 mg/pump actuation, 0.08 mg/pump actuation

, Spray, suspension, Nasal, Spray, suspension - Nasal, Aerosol, metered - Respiratory (inhalation), Respiratory (inhalation), Aerosol, metered, Suspension, Aerosol, metered; Suspension, Aerosol, metered; Suspension - Nasal, Suspension - Nasal, Powder, Powder - Respiratory (inhalation), Topical, Cream - Topical, Cream, Aerosol, metered - Nasal, Lotion - Topical, Lotion, Capsule - Respiratory (inhalation), Capsule, Spray - Nasal, Spray, Nasal; Respiratory (inhalation), Aerosol, metered - Nasal; Respiratory (inhalation)

Sinusitis

, 0.042 mg, 0.04 mg, 0.08 mg, 0.1 mg, 0.2 mg, 0.025 %, 0.25 mg/mL, 0.087 mg, 0.172 mg, 0.088 mg, 0.25 mg/pump actuation, 0.1 mg/pump actuation, 0.05 mg/pump actuation, 0.04 mg/pump actuation, 0.08 mg/pump actuation

, Spray, suspension, Nasal, Spray, suspension - Nasal, Aerosol, metered - Respiratory (inhalation), Respiratory (inhalation), Aerosol, metered, Suspension, Aerosol, metered; Suspension, Aerosol, metered; Suspension - Nasal, Suspension - Nasal, Powder, Powder - Respiratory (inhalation), Topical, Cream - Topical, Cream, Aerosol, metered - Nasal, Lotion - Topical, Lotion, Capsule - Respiratory (inhalation), Capsule, Spray - Nasal, Spray, Nasal; Respiratory (inhalation), Aerosol, metered - Nasal; Respiratory (inhalation)

Rhinitis, Allergic

, 0.042 mg, 0.04 mg, 0.08 mg, 0.1 mg, 0.2 mg, 0.025 %, 0.25 mg/mL, 0.087 mg, 0.172 mg, 0.088 mg, 0.25 mg/pump actuation, 0.1 mg/pump actuation, 0.05 mg/pump actuation, 0.04 mg/pump actuation, 0.08 mg/pump actuation

, Spray, suspension, Nasal, Spray, suspension - Nasal, Aerosol, metered - Respiratory (inhalation), Respiratory (inhalation), Aerosol, metered, Suspension, Aerosol, metered; Suspension, Aerosol, metered; Suspension - Nasal, Suspension - Nasal, Powder, Powder - Respiratory (inhalation), Topical, Cream - Topical, Cream, Aerosol, metered - Nasal, Lotion - Topical, Lotion, Capsule - Respiratory (inhalation), Capsule, Spray - Nasal, Spray, Nasal; Respiratory (inhalation), Aerosol, metered - Nasal; Respiratory (inhalation)

Sinusitis

, 0.042 mg, 0.04 mg, 0.08 mg, 0.1 mg, 0.2 mg, 0.025 %, 0.25 mg/mL, 0.087 mg, 0.172 mg, 0.088 mg, 0.25 mg/pump actuation, 0.1 mg/pump actuation, 0.05 mg/pump actuation, 0.04 mg/pump actuation, 0.08 mg/pump actuation

, Spray, suspension, Nasal, Spray, suspension - Nasal, Aerosol, metered - Respiratory (inhalation), Respiratory (inhalation), Aerosol, metered, Suspension, Aerosol, metered; Suspension, Aerosol, metered; Suspension - Nasal, Suspension - Nasal, Powder, Powder - Respiratory (inhalation), Topical, Cream - Topical, Cream, Aerosol, metered - Nasal, Lotion - Topical, Lotion, Capsule - Respiratory (inhalation), Capsule, Spray - Nasal, Spray, Nasal; Respiratory (inhalation), Aerosol, metered - Nasal; Respiratory (inhalation)

Rhinitis, Vasomotor

, 0.042 mg, 0.04 mg, 0.08 mg, 0.1 mg, 0.2 mg, 0.025 %, 0.25 mg/mL, 0.087 mg, 0.172 mg, 0.088 mg, 0.25 mg/pump actuation, 0.1 mg/pump actuation, 0.05 mg/pump actuation, 0.04 mg/pump actuation, 0.08 mg/pump actuation

, Spray, suspension, Nasal, Spray, suspension - Nasal, Aerosol, metered - Respiratory (inhalation), Respiratory (inhalation), Aerosol, metered, Suspension, Aerosol, metered; Suspension, Aerosol, metered; Suspension - Nasal, Suspension - Nasal, Powder, Powder - Respiratory (inhalation), Topical, Cream - Topical, Cream, Aerosol, metered - Nasal, Lotion - Topical, Lotion, Capsule - Respiratory (inhalation), Capsule, Spray - Nasal, Spray, Nasal; Respiratory (inhalation), Aerosol, metered - Nasal; Respiratory (inhalation)

Warnings

Beconase Aq has six contra-indications and should not be consumed with any of the conditions listed in the accompanying table.

Beconase Aq Contraindications

Condition

Risk Level

Notes

Cellulitis

Do Not Combine

Tuberculosis

Do Not Combine

Status Asthmaticus

Do Not Combine

infected skin lesions

Do Not Combine

Virus Diseases

Do Not Combine

Severe Hypersensitivity Reactions

Do Not Combine

Beclomethasone Dipropionate may interact with Pulse Frequency

There are 20 known major drug interactions with Beconase Aq.

Common Beconase Aq Drug Interactions

Drug Name

Risk Level

Description

2-Methoxyethanol

Major

The risk or severity of adverse effects can be increased when Beclomethasone dipropionate is combined with 2-Methoxyethanol.

9-(N-methyl-L-isoleucine)-cyclosporin A

Major

The risk or severity of adverse effects can be increased when Beclomethasone dipropionate is combined with 9-(N-methyl-L-isoleucine)-cyclosporin A.

Abatacept

Major

The risk or severity of adverse effects can be increased when Beclomethasone dipropionate is combined with Abatacept.

Abemaciclib

Major

The metabolism of Abemaciclib can be increased when combined with Beclomethasone dipropionate.

Abetimus

Major

The risk or severity of adverse effects can be increased when Beclomethasone dipropionate is combined with Abetimus.

Beconase Aq Toxicity & Overdose Risk

The toxic dose of beclometasone dipropionate for rats is greater than 3750mg/kg. Inhaling large amounts of this drug over a short period of time can cause problems with the HPA axis. Long-term use of this drug may lead to adrenal suppression.

image of a doctor in a lab doing drug, clinical research

Beconase Aq Novel Uses: Which Conditions Have a Clinical Trial Featuring Beconase Aq?

Condition

Clinical Trials

Trial Phases

Asthma

97 Actively Recruiting

Phase 1, Phase 4, Not Applicable, Early Phase 1, Phase 2, Phase 3

Skin Diseases

0 Actively Recruiting

Nasal Polyps

0 Actively Recruiting

corticosteroid responsive

0 Actively Recruiting

Hay Fever

0 Actively Recruiting

Sinusitis

0 Actively Recruiting

Cellulitis

0 Actively Recruiting

Rhinitis, Allergic

0 Actively Recruiting

Operation on nose

0 Actively Recruiting

Dermatosis

0 Actively Recruiting

Rhinitis, Vasomotor

1 Actively Recruiting

Not Applicable

Sinusitis

2 Actively Recruiting

Early Phase 1, Phase 2

Nasal Polyps

0 Actively Recruiting

Beconase Aq Reviews: What are patients saying about Beconase Aq?

5

Patient Review

4/12/2010

Beconase Aq for Inflammation of the Nose due to an Allergy

I had hay fever for 25 years and tried a bunch of different oral medications with no luck. Finally, a chemist recommended Beconase to me and it was an absolute lifesaver. I don't suffer from hay fever anymore, and I didn't experience any negative side effects that I'm aware of.

5

Patient Review

9/27/2016

Beconase Aq for Inflammation of the Nose

I've been using this nasal spray for over 25 years and it's the only one that really works for me. No side effects that I can tell, which is amazing.

5

Patient Review

9/5/2008

Beconase Aq for Inflammation of the Nose due to an Allergy

My husband has dealt with hay fever his entire life, but this medication has given him two symptom-free seasons. He's really happy about it!

5

Patient Review

12/18/2008

Beconase Aq for Inflammation of the Nose due to an Allergy

Beconase AQ has really helped me a lot. I'm finally able to live without worrying about my sinuses all the time.

5

Patient Review

3/4/2011

Beconase Aq for Inflammation of the Nose due to an Allergy

This medication has been incredible for me in managing my migraines. It's the only thing that works for me, and I've had no adverse effects from using it as directed.

3

Patient Review

6/9/2009

Beconase Aq for Inflammation of the Nose

After using this spray for two weeks, I gained eight pounds. Most of the weight was in my stomach area and I also experienced flatulent distension. It's been three months since I stopped using the spray and the weight hasn't gone down yet. This is the heaviest I've ever been.

2

Patient Review

3/18/2022

Beconase Aq for Inflammation of the Nose due to an Allergy

This brand is a subpar and irritating product that made my asthma worse, not better. I would be careful before using this brands' products.
image of drug pills surrounding a glass of water symbolizing drug consumption

Patient Q&A Section about beconase aq

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What is the generic name for Beconase AQ?

"There is not currently a generic form of Beconase AQ (beclomethasone), so it can be expensive, even with insurance."

Answered by AI

What is Beconase AQ used for?

"Beclomethasone prevents and treats seasonal and year-round allergy symptoms by reducing inflammation. It is often used to treat symptoms caused by other triggers, such as cigarette smoke or perfumes."

Answered by AI

Is Beconase AQ a steroid?

"Beconase AQ is a steroid that is used to treat different nasal symptoms such as congestion, sneezing and a runny nose. This is often caused by seasonal allergies or allergies that occur all year round. Beconase AQ is also used to prevent nasal polyps from returning after surgery to remove them."

Answered by AI

Is Beconase AQ over the counter?

"Relieves nasal allergy symptoms . Beconase AQ (beclomethasone) is a strong steroidal nasal spray that is available over the counter without a prescription. It is very effective at relieving nasal allergy symptoms, but is only available as brand so it may be expensive."

Answered by AI

Clinical Trials for Beconase Aq

Image of Allergy and Clinical Immunology Associates in Pittsburgh, United States.

Tilrekimig for Asthma

12 - 80
All Sexes
Pittsburgh, PA

The purpose of this clinical study is to learn about the safety and effects of the study medicine (called tilrekimig) for the potential treatment of severe asthma. Asthma is a condition that makes it challenging to breathe, which negatively impacts the quality of life of people who are affected. The study is seeking participants who: * Have a history of severe asthma for at least 12 months * Have had at least 2 asthma attacks (also known as exacerbations) within the last 12 months All participants will be given shots of study medicine or a placebo at the study clinic. Tilrekimig or the placebo will be given about every 4 weeks during the study. The study will compare the experiences of people receiving tilrekimig to those people who receive the placebo. This will help determine if tilrekimig is safe and effective.

Phase 3
Recruiting

Allergy and Clinical Immunology Associates (+2 Sites)

Pfizer CT.gov Call Center

Pfizer

Image of Ontario Tech University in Oshawa, Canada.

Temperature & Humidity Exposure for Asthma

11 - 18
All Sexes
Oshawa, Canada

The goal of this clinical study is to learn how different temperature and humidity conditions affect breathing, lung function, exercise capacity, symptoms, and other physical responses in children and youth aged 11 to 18 years with asthma, compared with age- and sex-matched children and youth without asthma. The main questions it aims to answer are: * How do different temperature and humidity conditions affect lung function, breathing symptoms, exercise capacity, and physiological responses in children and youth with asthma? * Do children and youth with asthma respond differently to these environmental conditions than children and youth without asthma? * Do sex and gender influence these responses? Researchers will compare children and youth with asthma to age- and sex-matched children and youth without asthma to see if temperature and humidity exposures have different effects on breathing, exercise performance, symptoms, and physiological responses. Participants will: * Attend two study visits in a climate-controlled chamber. * Be exposed to hot, cold, and varying humidity conditions for short periods of time. * Complete breathing tests and exercise testing before, during, and after each exposure. * Have symptoms, physical activity, and physiological responses monitored throughout the study.

Waitlist Available
Has No Placebo

Ontario Tech University

Image of Children's Hospital Los Angeles in Los Angeles, United States.

Wearable Stethoscope for Childhood Asthma

4 - 17
All Sexes
Los Angeles, CA

The goal of this clinical trial is to evaluate a prototype wearable stethoscope designed to record lung sounds and assess asthma control in children and adolescents with asthma aged 4 to 17 years who are able to perform spirometry. The study aims to determine whether the prototype wearable stethoscope can accurately detect clinically meaningful changes in lung sounds associated with asthma control and response to bronchodilator treatment. The main questions it aims to answer are: * Does the prototype wearable stethoscope demonstrate agreement with recordings obtained from commercially available Thinklabs One Digital Stethoscopes in identifying normal and abnormal lung sounds? * Are lung sounds detected by the prototype wearable stethoscope associated with asthma symptom control as measured by the Childhood Asthma Control Test (cACT) or Asthma Control Test (ACT) Researchers will compare recordings obtained from the prototype wearable stethoscope with recordings obtained from FDA-cleared Thinklabs One Digital Stethoscopes to evaluate the prototype device's ability to detect abnormal lung sounds and changes in lung sounds following bronchodilator treatment.

Waitlist Available
Has No Placebo

Children's Hospital Los Angeles

Roberta Kato, MD

Have you considered Beconase Aq clinical trials?

We made a collection of clinical trials featuring Beconase Aq, we think they might fit your search criteria.
Go to Trials
Image of SMS Clinical Research LLC in Garland, United States.

Tilrekimig for Severe Asthma

12 - 80
All Sexes
Garland, TX

The purpose of this clinical study is to learn about the safety and effects of the study medicine (called tilrekimig) for the potential treatment of severe asthma. Asthma is a condition that makes it challenging to breathe, which negatively impacts the quality of life of people who are affected. The study is seeking participants who: * Have a history of severe asthma for at least 12 months * Have had at least 2 asthma attacks (also known as exacerbations) within the last 12 months All participants will be given shots of study medicine or a placebo at the study clinic. The study will compare the experiences of people receiving tilrekimig to those people who receive the placebo. This will help determine if tilrekimig is safe and effective.

Phase 3
Recruiting

SMS Clinical Research LLC (+6 Sites)

Pfizer CT.gov Call Center

Pfizer

Have you considered Beconase Aq clinical trials?

We made a collection of clinical trials featuring Beconase Aq, we think they might fit your search criteria.
Go to Trials
Image of Pfizer Clinical Research Unit - New Haven in New Haven, United States.

PF-08103402 for Asthma

18 - 65
All Sexes
New Haven, CT

The purpose of this study is to learn about the safety of a new study medicine called PF-08103402 in healthy adults (do not have disease) and or in adults with mild-to-moderate asthma. This is the first time the study medicine is being given to people. For Parts A, B, C, D and F, the study is seeking participants who: * Are healthy (do not have disease) males or females who can no longer have children, * Are 18 to 65 years old, * Have a body mass index (BMI) of 16 to 32 kilograms per meter squared and a body weight of more than 50 kilograms (110 pounds). Body mass index is a way to measure body fat by using a person's height and weight For Part A (optional group or cohort 3: Japanese participants only): * A body weight of more than 45 kilograms (100 pounds). * Have 4 biological Japanese grandparents who were born in Japan. For Part E only: * Adults with a documented history of asthma (confirmed by a doctor) for at least 12 months before entering the study. * Have a body mass index (BMI) of 16 to 35 kilograms per meter squared and a total body weight of more than 50 kilograms (110 pounds). The study has six parts: Part A, Part B, Part C, Part D, Part E and Part F. The study medicine will be taken as a suspension or tablet by mouth 1 time a day (except in Parts B and E where it will be taken 1 time a day for 14 days) at the study clinic. The study will help understand: * how the body processes the study medicine in healthy participants (Parts A and B), * how much of the study medicine gets into the bloodstream and if food affects the amount of study medicine in the blood in healthy participants (Part C), * how the study medicine is broken down and leaves the body in healthy participants (Optional Part D), * how the study medicine is processed in adults with mild-to-moderate asthma (Optional Part E), * if taking the study medicine together with another medicine affects how each medicine is processed by the body in healthy participants (Optional Part F). Participants will take part in the study for about 10 weeks (Parts A and F), 12 weeks (Part B), 9 weeks (Parts C and D), and 16 weeks (Part E). During this time, they will have 2 study visits at the study clinic and up to 28 overnight stays (Part A), 18 overnight stays (Parts B and E), 10 overnight stays (Part C), 11 overnight stays (Part D), and 16 overnight stays (Part F). The study team will also call participants 1 time over the phone at the end of the study to assess how they are doing. Study measurements will be taken by body examination, monitoring side effects, blood and urine tests, heart tests (ECG), vital signs (blood pressure, pulse and respiratory rate), questionnaires (Parts C and E), stool samples (Part D only), and breathing tests (Part E only).

Phase 1
Recruiting

Pfizer Clinical Research Unit - New Haven

Pfizer CT.gov Call Center

Pfizer

Image of Taddle Creek Family Health Team (Bay Street) in Toronto, Canada.

Eco-Friendly Inhaler Prescribing for Asthma

Any Age
All Sexes
Toronto, Canada

The goal of this study is to determine whether an 'eco' version of the Electronic Asthma Management System (eAMS) can reduce inhaler carbon emissions in primary care, in patients with asthma. The existing eAMS uses patient-specific criteria (asthma control, asthma flare-up risk, and current medications) to provide guideline-based computerized clinical decision support to clinicians, to improve the delivery of asthma care. The eAMS-Eco includes embedded cues and messaging on the environmental impact of inhaler medications and links to a patient-friendly conversation aid that facilitates shared decision-making and climate-conscious prescribing. The study will evaluate the implementation of the eAMS-Eco in two primary care clinics that have been using the existing eAMS, using an interrupted time-series analysis (one year pre- and post-launch of the eAMS-Eco). The investigators will assess system uptake and user feedback on the eAMS-Eco, as well as changes in inhaler prescriptions (including resulting changes in carbon emissions and costs) and changes in asthma control, in the implementation period (eAMS-Eco) compared to the baseline period (eAMS).

Waitlist Available
Has No Placebo

Taddle Creek Family Health Team (Bay Street) (+3 Sites)

Have you considered Beconase Aq clinical trials?

We made a collection of clinical trials featuring Beconase Aq, we think they might fit your search criteria.
Go to Trials